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Abstract 
 
Background 
This study assesses the efficacy of three granulocyte colony-stimulating factors (G-CSFs; 
pegfilgrastim, filgrastim and lenograstim) in preventing febrile neutropenia (FN). 
 
Methods 
A systematic review was undertaken. Head-to-head studies were combined using direct 
meta-analyses. In addition, an indirect Bayesian mixed treatment comparison (MTC) was 
undertaken to facilitate comparison between G-CSFs where there were no direct trials, and 
to allow data from all trials to be synthesised into a coherent set of results. 
 
Results 
The review identified the following studies comparing G-CSF prophylaxis to no primary G-
CSF prophylaxis: 5 studies of pegfilgrastim, 9 studies of filgrastim and 5 studies of 
lenograstim. In addition, 5 studies were identified comparing pegfilgrastim to filgrastim. The 
two synthesis methods (meta-analysis and MTC) demonstrated that all three G-CSFs 
significantly reduced FN rate. Pegfilgrastim reduced FN rate to a greater extent than 
filgrastim (significantly in the head-to-head meta-analysis and in the MTC of all studies, and 
not quite significantly when the MTC was restricted to RCTs only). In the absence of direct 
trials, the MTC gave an 80-86% probability that pegfilgrastim is superior to lenograstim in 
preventing FN, and a 71-72% probability that lenograstim is superior to filgrastim. 
 
Conclusions 
Prophylaxis with G-CSFs significantly reduces FN rate. A head-to-head meta-analysis shows 
pegfilgrastim to be significantly superior to filgrastim in preventing FN events, while an MTC 
demonstrates that pegfilgrastim is likely to be superior to lenograstim. 
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Introduction 
 
Neutropenia is the major dose-limiting toxicity of many chemotherapy regimens. Febrile 
neutropenia (FN) is defined as neutropenia with fever, usually indicating infection, and is 
associated with substantial morbidity, mortality, and costs.[1] Grade 3-4 neutropenia is 
defined as a neutrophil count either <1.0 x 109/L or <0.5 x 109/L. The direct risk of mortality 
associated with FN has been estimated as 9.5% (95% CI: 9.2%, 9.8%) in a study of 41,779 
cancer patients hospitalised with FN.[1] Management of FN often requires lengthy 
hospitalisation,[1] with associated costs and detrimental effects on quality of life.[2;3] In 
addition, an FN episode has been shown to increase the risk of chemotherapy dose 
reductions and delays.[4] Unplanned reductions in chemotherapy dose may cause further 
deaths from cancer in the long-term; in a retrospective analysis of breast cancer patients with 
a 30-year follow-up, the survival rate was 40% (95% CI: 26%, 55%) among patients receiving 
at least 85% of their planned dose intensity, but only 21% (95% CI: 14%, 26%) among 
patients who received less than 85%.[5] 
 
Recombinant human granulocyte colony-stimulating factors (G-CSFs) stimulate production of 
mature, functional neutrophils.[6] G-CSFs have been shown to reduce the incidence of FN 
when used as prophylaxis following chemotherapy.[7-28] Three G-CSFs are currently in use: 
filgrastim, pegfilgrastim, and lenograstim. Filgrastim and lenograstim are administered as a 
series of daily injections; clinical studies suggest an average of 11 injections per 
chemotherapy cycle are required to achieve recovery of the absolute neutrophil count (ANC) 
to within the normal range.[11;12;24;25] Pegfilgrastim is given as a single injection per 
chemotherapy cycle.[29;30] G-CSFs may be administered as primary prophylaxis (in every 
chemotherapy cycle from cycle 1) or as secondary prophylaxis (in all remaining cycles 
following an FN event or prolonged severe neutropenia). The overall FN risk is dependent on 
chemotherapy regimen as well as individual patient risk factors such as age, performance 
status and disease stage.[31] Guidelines from the European Organisation for Research and 
Treatment of Cancer (EORTC),[31] the American Society of Clinical Oncology (ASCO)[32] 
and the National Comprehensive Cancer Network (NCCN)[33] recommend that prophylactic 
G-CSFs should be used where the risk of FN associated with the chemotherapy regimen is 
greater than or equal to 20%, and may be considered where the risk is 10-20%, particularly 
where additional patient risk factors are present. 
 
The aim of this study is to assess the relative efficacy of the three G-CSFs (pegfilgrastim, 
filgrastim and lenograstim) in preventing FN, using both direct head-to-head meta-analyses 
and a Bayesian mixed treatment comparison. 
 
 
 
Methods 
 
Obtaining data on the efficacy of each intervention 
Two systematic reviews and meta-analyses of G-CSFs in relation to reducing FN events 
have been published.[34;35] Kuderer et al.[34] analysed studies of primary G-CSF 
prophylaxis (pegfilgrastim, filgrastim or lenograstim) versus no primary G-CSF prophylaxis, 
whilst Pinto et al.[35] analysed studies of primary prophylaxis with pegfilgrastim versus 
filgrastim. The literature searches within these existing reviews were conducted during 2006. 
 
A systematic search was undertaken to identify further studies of pegfilgrastim, filgrastim or 
lenograstim for FN prophylaxis during chemotherapy, compared to each other or to no 
primary prophylaxis, published between January 2006 and June 2009. The following 
databases were searched: Medline, EMBASE, the Cochrane Database of Systematic 
Reviews, the Cochrane CENTRAL Register of Controlled Trials, the Database of Abstracts of 
Reviews of Effects (DARE), the Health Technology Assessment Database and the NHS 
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Economic Evaluation Database (NHS-EED). The Medline search strategy was designed with 
reference to the previous two reviews, and comprised subject headings (granulocyte colony-
stimulating factor; granulocyte colony-stimulating factor recombinant; colony-stimulating 
factors recombinant; filgrastim) as well as text words (G-CSF; granulocyte colony-stimulating 
factor; filgrastim; Neupogen; pegfilgrastim; Neulasta; lenograstim; Granocyte; Euprotin; r-
metHuG-CSF; SD-01; PEG-rmetHuG-CSF). Searches were not restricted by language. 
Bibliographies of retrieved papers were hand-searched and experts in the field were 
consulted, according to the QUOROM statement for reporting of systematic reviews.[36] 
 
Studies were considered suitable for inclusion if they compared the prophylactic efficacy of a 
G-CSF (pegfilgrastim, filgrastim or lenograstim) at any dose to another G-CSF or to no 
primary G-CSF prophylaxis, for the prevention of FN. For consistency with the two existing 
systematic reviews,[34;35] only studies of adult cancer patients with solid tumours or 
lymphoma were included. Studies allowing concomitant antibiotic prophylaxis were included 
if this was administered in both study arms. The following study types were excluded: studies 
of G-CSFs for treatment of FN; studies in children; studies in patients with leukaemia, 
myeloid malignancies or myelodysplastic syndromes (due to limited safety and efficacy data 
in these conditions); studies of G-CSFs for stem cell mobilisation in bone marrow or 
peripheral blood stem cell transplantation; economic analyses; studies with differing drugs, 
doses or schedules of chemotherapy in each arm; and studies with differing doses of the 
same G-CSF in each arm. 
 
This study was undertaken alongside the development of an economic model, and FN was 
chosen as the key clinical outcome both in the economic model and in this review, due to its 
direct bearing on morbidity, mortality and hospitalisation rates. Therefore the outcome 
measure assessed in this analysis was the incidence of FN over all cycles of chemotherapy 
within each clinical study. Data was extracted by two reviewers using a form developed for 
this review and any discrepancies resolved through discussion. 
 
Meta-analysis of head-to-head studies 
Meta-analyses were undertaken to compare the effectiveness of G-CSFs versus no 
prophylaxis and versus each other in prevention of FN, where comparative studies were 
available. This was undertaken using RevMan software (version 4.2.10, Cochrane 
Collaboration). Due to heterogeneity between studies, random effects models were used. 
 
Bayesian mixed treatment comparison (MTC) 
To strengthen the validity of the results, and also to provide an indirect comparison where 
head-to-head trials were not available (i.e. to compare lenograstim to the other G-CSFs), a 
mixed treatment comparison (MTC)[37] of the entire dataset was carried out using the 
Bayesian modelling software WinBugs.[38] Where there are trials comparing interventions 
both to no treatment and to other interventions, an MTC synthesises all the trials into a single 
network and uses the evidence from all the trials to estimate a relative risk for each 
comparison. This allows for estimates of treatment effect to ‘borrow strength’ from all studies 
in the network.[39] The Bayesian approach allows analysis which differs from testing for 
statistical significance at conventional levels (such as 95%), and enables estimation of a 
percentage likelihood that one treatment is more efficacious than another. A random-effects 
model was again used, due to heterogeneity between studies. Median values are given for 
the point estimates of the relative risks, for consistency with standard meta-analysis. 
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Results 
 
Number and characteristics of included studies 
The QUOROM flow chart for study inclusion is shown in Figure 1. The included studies are 
described in Table 1. In total, 22 citations relating to 24 studies satisfied the inclusion criteria: 
5 studies of pegfilgrastim vs. no primary G-CSF[7-10]; 9 studies of filgrastim vs. no primary 
G-CSF;[16-23] 5 studies of primary lenograstim vs. no primary G-CSF;[24-28] and 5 studies 
of primary pegfilgrastim vs. primary filgrastim.[11-15] No studies were identified comparing 
lenograstim to either pegfilgrastim alone or filgrastim alone. The network of trials for the 
mixed treatment comparison is shown in Figure 2. 
 
Our literature search identified 4 additional studies of pegfilgrastim vs. no primary G-CSF, in 
addition to the single RCT in breast cancer patients[7] reported in an existing systematic 
review.[34] These additional studies included an RCT in elderly breast cancer patients,[9] 
RCTs in lymphoma patients and solid tumour patients (reported as a single citation),[8] and a 
large non-randomised study in which the study arms were generated by successive protocol 
amendments allowing greater levels of prophylaxis as the toxicity of TAC chemotherapy 
became apparent.[10] Filgrastim and lenograstim were generally given for 10-14 days where 
the chemotherapy cycle length was 3 weeks (and for fewer days in a small number of trials 
with shorter cycle lengths). The comparator arm in some of the studies included secondary 
G-CSFs for those patients having an FN event. 
 
There was heterogeneity among trials of all three G-CSFs in terms of their clinical population 
(age, cancer type, chemotherapy regimen, number of chemotherapy cycles; see Table 1) 
and in terms of their efficacy results (Tables 2 and 3). As already reported in previous 
reviews, study quality was mixed,[34;35] with some studies being open-label rather than 
double-blind (Table 1). However, there was insufficient data to analyse the populations 
separately. Therefore, for consistency with existing reviews and to provide a clinical overview 
and avoid risk of bias, all RCTs were included in the main analysis. An additional analysis 
was also undertaken including a non-randomised study which was considered potentially 
relevant for inclusion. The recruitment of participants to each arm appeared to be unbiased 
(the different study arms were generated following protocol amendments requiring additional 
FN prophylaxis due to the toxicity of the chemotherapy regimen), and patient characteristics 
appeared similar between arms.[10] 
 
Efficacy of G-CSFs in preventing febrile neutropenia 
The incidence of FN across all chemotherapy cycles for all included studies is shown in 
Table 2. The pooled results for each comparison are summarised in Table 3, firstly using a 
meta-analysis of head-to-head trial data, and secondly using a Bayesian MTC. 
 
Both the meta-analyses and the MTC indicated that each of the G-CSFs significantly 
decreases the risk of FN compared to no primary G-CSF (Table 3). At the time of the 
previously-reported meta-analysis,34 only a single trial of pegfilgrastim vs. no primary G-CSF 
had been published.7 This review strengthens the evidence base by including further trials of 
pegfilgrastim vs. no primary G-CSF.[8-10] Following the addition of these studies, 
pegfilgrastim remained significantly more efficacious than no primary G-CSF in preventing 
FN, with the meta-analysis of RCTs giving a relative risk for FN of 0.31 (95% CI: 0.12, 0.76). 
If including the non-randomised study,[10] this became 0.29 (95% CI: 0.15, 0.55). The MTC 
based on analysis of RCTs gave a relative risk of 0.36 (95% credible interval 0.22, 0.61); this 
became 0.34 (95% credible interval: 0.23, 0.54) if the non-randomised study[10] was 
included. 
 
Filgrastim and lenograstim also decreased the risk of FN compared to no primary G-CSF, 
with the head-to head meta-analyses giving relative risks for FN of 0.61 (95% CI: 0.53, 0.72) 
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for filgrastim and 0.62 (95% CI: 0.44, 0.88) for lenograstim, as described in a previous 
review.34 The relative risks generated by the MTC are shown in Table 3. 
 
The head-to-head meta-analysis showed primary pegfilgrastim to be significantly more 
efficacious than primary filgrastim in preventing FN. This was also demonstrated in the MTC 
of all studies, but was not quite significant when the MTC was restricted to RCTs only (Table 
3). 
  
There were no head-to-head trials of lenograstim vs. the other G-CSFs; however, the MTC 
allows us to make an estimation of comparative efficacy. The relative risk of FN for 
pegfilgrastim vs. lenograstim based on analysis of RCTs was estimated as 0.75 (95% 
credible interval: 0.38, 1.60), equating to an 80% probability that pegfilgrastim is superior to 
lenograstim in preventing FN. Based on analysis of all studies including the non-randomised 
study, the relative risk was 0.71 (95% credible interval: 0.39, 1.42), with an 86% probability 
that pegfilgrastim is superior to lenograstim. The relative risk of FN for lenograstim vs. 
filgrastim based on analysis of RCTs was estimated as 0.88 (95% credible interval: 0.49, 
1.40), equating to a 72% probability that lenograstim is superior to filgrastim in preventing 
FN. Based on analysis of all studies including the non-randomised study, the relative risk 
was 0.88 (95% credible interval: 0.49, 1.41), with an 71% probability that lenograstim is 
superior to filgrastim. 
 
 
 
 
Discussion 
 
Our analysis updates the findings of previous reviews by incorporating further trials of 
pegfilgrastim vs. no primary G-CSF (only a single trial made this comparison at the time of 
the existing review).[7;34] In addition, the MTC allowed comparison of lenograstim to the 
other G-CSFs in the absence of head-to-head trials. 
 
Our results confirm that primary prophylaxis with G-CSFs is effective in reducing the risk of 
FN; this was the conclusion reached by Kuderer et al.,[34] and we show that this holds 
following the inclusion of the additional studies of pegfilgrastim vs. no primary G-CSF. Our 
results also allow comparison of the relative FN risk reduction between the “once-per-cycle” 
G-CSF pegfilgrastim and the “once-daily” G-CSFs filgrastim and lenograstim. As described 
by Pinto et al.,[35] pegfilgrastim reduced FN to a greater extent than filgrastim (this was 
significant in the head-to-head meta-analysis and in the MTC of all studies, though not quite 
significant in the MTC of RCTs only). Our MTC analysis demonstrates that, in the absence of 
direct trials, there is an 80-86% probability that pegfilgrastim is superior to lenograstim in 
preventing FN. 
 
As discussed in previous reviews,[34;35] there was heterogeneity among the studies in 
terms of the clinical population studied, which varied in terms of cancer type, chemotherapy 
regimen and patient age. Correspondingly, heterogeneity was observed among the study 
results. Since there was insufficient data to analyse the various populations separately, it 
was felt to be most clinically useful to include all studies in the analysis. The included studies 
covered a range of populations and treatment regimens, as would be observed in clinical 
practice. This variation in clinical population, and the corresponding high levels of 
heterogeneity, indicate that caution should be used when applying the results to individual 
clinical settings. 
 
One aspect of heterogeneity is the fact that different chemotherapy regimens are associated 
with differing “baseline” FN risks in the absence of G-CSF prophylaxis. As described by 
Kuderer et al.,[34] there is a suggestion that studies with a lower baseline FN risk may 
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demonstrate a greater reduction in the relative risk of FN when G-CSF prophylaxis is 
administered. For example, the Vogel et al. study[7] of docetaxel (100mg/m2) demonstrated a 
relatively low baseline FN risk of 17% in the control arm and a corresponding large reduction 
in FN risk in the pegfilgrastim arm (relative risk of 0.08). However, Kuderer et al. 
demonstrated that if the one or two studies with the lowest baseline FN risk were excluded 
from the analysis, no significant relationship between relative risk and baseline FN risk was 
observed.[34] Our analysis produced similar results (data not reported). Future studies in 
populations with differing baseline FN risks may shed further light on this issue. 
 
It may also be relevant to note that the majority of the studies with a 3-week chemotherapy 
cycle length administered filgrastim and lenograstim until ANC recovery as recommended in 
the product labels (generally for 10-11 days per cycle), while in clinical practice these G-
CSFs may sometimes be given for a shorter number of days, which may impact on 
efficacy.[40;41] 
 
Our findings are also relevant in terms of methodologies for evidence synthesis. MTC 
methods enable comparison of efficacy using a single consistent dataset incorporating data 
from all trials. In this review, the MTC allowed assessment of the consistency of the direct 
and indirect evidence for the efficacy of the three G-CSFs in preventing FN. The fact that 
both methods gave similar results adds weight to the findings. Also, as there are no direct 
trials of lenograstim against other G-CSFs, the MTC allowed estimation of the relative 
effectiveness of lenograstim using the indirect evidence. 
 
 
 
 
Conclusions 
 
This analysis incorporates recent trials of pegfilgrastim vs. no primary G-CSF and confirms 
that primary prophylaxis with G-CSFs is effective in reducing the risk of FN. A head-to-head 
meta-analysis shows pegfilgrastim to be significantly superior to filgrastim in preventing FN 
events, while a Bayesian MTC demonstrates that pegfilgrastim is likely to be superior to 
lenograstim in reducing FN events. 
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Figure 1: QUOROM flow chart for identification of relevant studies 
 
 Potentially relevant citations 
identified and screened for retrieval:
     N = 2066 citations 
 
 
 
 
Citations rejected at title or 
abstract stage: 
     N = 2057 citations 
Total full papers included, from updated search and previous reviews: 
Citations rejected at full 
text stage: 
     N = 6 citations 
Additional studies identified since previous reviews: 
     N = 3 citations relating to 4 studies: 
 Pegfilgrastim vs no primary G-CSF: 4 additional studies 
(3 RCTs within 2 citations, plus 1 non-randomised study) 
     N = 22 citations relating to 24 studies: 
 Pegfilgrastim vs no primary G-CSF: 5 studies (4 RCTs within 3 
citations, plus 1 non-randomised study) 
 Filgrastim vs no primary G-CSF: 9 RCTs 
 Lenograstim vs no primary G-CSF: 5 RCTs 
 Pegfilgrastim vs filgrastim: 5 RCTs 
 Pegfilgrastim vs lenograstim: 0 studies 
 Lenograstim vs filgrastim: 0 studies 
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Figure 2: Network of trials for mixed treatment comparison 
 
 
Filgrastim Pegfilgrastim 
No primary 
G-CSF prophylaxis 
5 studies (4 RCTs) 
Total N = 1819 (RCTs only) or 2386 (all studies) 
5 studies 
Total N = 606 
9 studies 
Total N = 1835 
5 studies 
Total N = 467 
Lenograstim 
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Table 1: Description of trials of primary G-CSFs (vs. no primary G-CSF, or vs. each other) 
 
Trial Study 
design 
Cancer 
type 
Cancer 
stage 
Patient 
age 
Chemotherapy 
regimen 
No of 
cycles 
(max) 
Cycle 
length 
Arm 1 G-CSF 
strategy* 
Arm 1: N 
analyse
d 
Arm 1: 
days 
primary 
G-CSF 
Arm 2 G-CSF 
strategy* 
Arm 2: N 
analysed 
Arm 2: 
days 
primary 
G-CSF 
Pegfilgrastim vs. no primary G-CSF 
Vogel 
2005[7] 
RCT, 
phase III, 
DB 
Breast 
cancer 
62% stage 
IV, 38% 
other 
stages 
Mean 
age 52, 
range 21-
88 
Docetaxel 
100mg/m2 
4 3 weeks Pegfilgrastim 
primary: 6mg day 2 
463 1 Placebo primary, 
pegfilgrastim 
secondary† 
465 0 
Balducci 
2007: 
solid 
tumour#[
8] 
RCT, OL Solid 
tumour 
(lung, 
ovarian, 
breast) 
31% stage 
I-II, 69% 
stage III-IV 
Age ≥65. 
Median 
72, range 
65-88 
One of 15 
regimens with 
mild-to-
moderate risk of 
neutropenia 
6 3 weeks Pegfilgrastim 
primary: 6mg day 2 
343 1 No primary G-CSF, 
pegfilgrastim 
secondary††† 
343 0 
Balducci 
2007: 
NHL#[8] 
RCT, OL NHL 38% stage 
I-II, 62% 
stage III-IV 
Age ≥65. 
Median 
72, range 
65-88 
CHOP or R-
CHOP 
6 3 weeks Pegfilgrastim 
primary: 6mg day 2 
73 1 No primary G-CSF, 
pegfilgrastim 
secondary††† 
73 0 
Romieu 
2007#[9] 
RCT, 
phase II, 
OL 
Breast 
cancer 
Stage II-III, 
node-
positive 
Age ≥65. 
Median 
68, range 
65-77 
FEC-100 6 (FN 
reported 
cycle 1 
only) 
3 weeks Pegfilgrastim 
primary: 6mg day 2 
30 1 No primary G-CSF, 
pegfilgrastim 
secondary†† 
29 0 
von 
Minckwit
z 
2008#[10
] 
Not RCT; 
study arms 
from 
successive 
protocol 
amendment
s 
Breast 
cancer 
74% stage 
I-II, 26% 
stage III-IV 
Age ≥18 TAC 8 3 weeks Pegfilgrastim 
primary: 6mg day 2 
+ primary antibiotic 
prophylaxis 
314 1 No primary G-CSF; 
primary antibiotic 
prophylaxis; 
filgrastim / 
lenograstim 
secondary†† 
253 0 
Filgrastim vs. no primary G-CSF 
Doorduij
n 
2003[16] 
RCT, OL Aggressi
ve NHL 
Stage II-IV Age ≥65. 
Median 
72, range 
65-90 
CHOP 6 to 8 3 weeks Filgrastim primary: 
300ug/d from day 2 
for 10d 
197 10 No primary G-CSF 192 0 
Osby 
2003 
(CHOP)[
17] 
RCT, OL Aggressi
ve NHL 
Stage II-IV Age ≥60. 
Range 
60-86 
CHOP 4 to 8 
(most 8) 
3 weeks Filgrastim primary: 
5ug/kg/d from day 2 
up to 14d or until 
ANC=10x109/l 
101 10 to 14 No primary G-CSF 104 0 
Osby 
2003 
(CNOP)[
17] 
RCT, OL Aggressi
ve NHL 
Stage II-IV Age ≥60. 
Range 
60-86 
CNOP 4 to 8 
(most 8) 
3 weeks Filgrastim primary: 
5ug/kg/d from day 2 
up to 14d or until 
ANC=10x109/l 
125 10 to 14 No primary G-CSF 125 0 
Trial Study 
design 
Cancer 
type 
Cancer 
stage 
Patient 
age 
Chemotherapy 
regimen 
No of 
cycles 
(max) 
Cycle 
length 
Arm 1 G-CSF 
strategy* 
Arm 1: N 
analyse
d 
Arm 1: 
days 
primary 
G-CSF 
Arm 2 G-CSF 
strategy* 
Arm 2: N 
analysed 
Arm 2: 
days 
primary 
G-CSF 
Zinzani 
1997[18] 
RCT, OL Aggressi
ve NHL 
 Stage II-IV Age ≥60. 
Age 
range 60-
82 
VNCOP-B 8 1 week 
(differs 
alternate 
weeks) 
Filgrastim primary: 
5ug/kg/d from day 
3; prophylactic 
antibiotics 
77 5 No primary G-CSF; 
prophylactic 
antibiotics 
72 0 
Pettenge
ll 
1992[19] 
RCT, OL Aggressi
ve NHL 
Any stage Age 
range 16-
71 
VAPEC-B 11 1 week 
(differs 
alternate 
weeks) 
Filgrastim primary: 
230ug/m2/d from 
day 2 up to 14d or 
until ANC=10x109/l; 
prophylactic 
antibiotics 
41 12 No primary G-CSF; 
prophylactic 
antibiotics 
39 0 
Timmer-
Bonte 
2005[20] 
RCT, 
phase III, 
OL 
SCLC 69% 
extensive, 
31% 
limited 
Age 
range 36-
81 
CDE 5 3 weeks Filgrastim primary: 
300/450ug/d from 
day 4; prophylactic 
antibiotics 
90 10 No primary G-CSF; 
prophylactic 
antibiotics 
85 0 
Trillet-
Lenoir 
1993[21] 
RCT, DB SCLC 64% 
extensive, 
36% 
limited 
Median 
59 
CDE 6 3 weeks Filgrastim primary: 
230ug/m2/d from 
day 4 up to 14d or 
until ANC=10x109/l 
65 9 to 14 Placebo primary 64 0 
Crawford 
1991[22] 
RCT, DB SCLC 72% 
extensive, 
28% 
limited 
Age 
range 31-
80 
CDE 6 3 weeks Filgrastim primary: 
230ug/m2/d from 
day 4 up to 14d or 
until ANC=10x109/l 
95 9 to 14 Placebo primary; 
secondary G-CSF 
104 0 
Fossa 
1998[23] 
RCT, 
phase III, 
OL 
Germ cell 
cancer 
Metastatic, 
poor-
prognosis 
Age 
range 15-
65 
BEP/EP or 
BOP/VIP-B 
6 3 weeks 
or 10 d 
Filgrastim primary: 
5ug/kg/d from day 3 
or 6 
129 7 or 14 No primary G-CSF 130 0 
Lenograstim vs. no primary G-CSF 
Chevalli
er 
1995[24] 
RCT, DB Breast 
cancer, 
inflamma
tory 
Non-
metastatic 
Age 
range 23-
65 
FEC-high-dose 4 3 weeks Lenograstim 
primary: 5ug/kg/d 
from day 6 
61 10 Placebo primary 59 0 
Gisselbr
echt 
1997[26] 
RCT, DB Aggressi
ve NHL 
 Any stage Age 
range 15-
55 
LNH-87 (LNH-
84 + 
randomization to 
anthracyclines) 
4 2 weeks Lenograstim 
primary: 5ug/kg/d 
from day 6 
82 8 Placebo primary 80 0 
Bui 
1995[25] 
RCT, DB Soft 
tissue 
sarcoma 
Metastatic 
or locally 
advanced 
Age 
range 21-
69 
MAID 6 (FN 
reported 
cycle 1 
only) 
3 weeks Lenograstim 
primary: 5ug/kg/d 
from day 4 up to 
14d or until 
ANC=30x109/l 
22 10 to 14 Placebo primary; 
secondary G-CSF 
26 0 
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Trial Study 
design 
Cancer 
type 
Cancer 
stage 
Patient 
age 
Chemotherapy 
regimen 
No of 
cycles 
(max) 
Cycle 
length 
Arm 1 G-CSF 
strategy* 
Arm 1: N 
analyse
d 
Arm 1: 
days 
primary 
G-CSF 
Arm 2 G-CSF 
strategy* 
Arm 2: N 
analysed 
Arm 2: 
days 
primary 
G-CSF 
Gebbia 
1994[27] 
RCT, DB Various Advanced Age 
range 40-
75 
Various Various Various Lenograstim 
primary: 5ug/kg/d 
23 ≥7d Placebo primary 28 0 
Gebbia 
1993[28] 
RCT, DB Various Advanced Age 
range 38-
66 
Various Various Various Lenograstim 
primary: 5ug/kg/d 
43 7 to 10 Placebo primary 43 0 
Pegfilgrastim vs. 10- or 11-day filgrastim 
Green 
2003[11] 
RCT, 
phase III, 
DB 
Breast 
cancer 
28% stage 
II, 27% 
stage III, 
45% stage 
IV 
Mean 
age 52, 
range 30-
75 
Doxorubicin 
60mg/m2 
/docetaxel 
75mg/m2 
4 3 weeks Pegfilgrastim 
primary: 6mg day 2; 
then placebo up to 
14d 
77 1 Filgrastim primary: 
5ug/kg, from day 2 
up to 14d or until 
ANC=10x109/l 
75 11 
(median) 
Holmes 
2002: 
phase 
III[12] 
RCT, 
phase III, 
DB 
Breast 
cancer 
High-risk 
stage II, III 
or IV. 37% 
stage IV 
Mean 
age 51 
Doxorubicin 
60mg/m2 
/docetaxel 
75mg/m2 
4 3 weeks Pegfilgrastim 
primary: 100ug/kg 
day 2; then placebo 
up to 14d 
149 1 Filgrastim primary: 
5ug/kg, from day 2 
up to 14d or until 
ANC=10x109/l 
147 11 
(mean) 
Holmes 
2002: 
phase 
II[13] 
RCT, 
phase II, 
DF 
Breast 
cancer 
High-risk 
stage II, III 
or IV. 30% 
stage IV 
Mean 
age 49 
Doxorubicin 
60mg/m2 
/docetaxel 
75mg/m2 
4 3 weeks Pegfilgrastim 
primary: 100ug/kg 
day 2 (other dose 
groups not included 
here) 
46 1 Filgrastim primary: 
5ug/kg, from day 2 
up to 14d or until 
ANC=10x109/l 
25 10.6; 
10.2; 
10.4; 
11.0 
(mean in 
cycles 1-
4) 
Grigg 
2003[14] 
RCT, 
phase II, 
OL, DF 
NHL Any stage Age ≥60. 
Mean 68, 
range 60-
82 
CHOP 6 3 weeks Pegfilgrastim 
primary: 100ug/kg 
day 2 (other dose 
groups not included 
here) 
14 1 Filgrastim primary: 
5ug/kg, from day 2 
up to 14d or until 
ANC=10x109/l 
13 10 
(mean) 
Vose 
2003[15] 
RCT, 
phase II, 
OL 
NHL 
(n=56) or 
HL (n=4) 
Relapsed 
or 
refractory 
Mean 
age 49. 
85% <65 
ESHAP 4 (FN 
reported 
cycles 1 
& 2 only) 
3 weeks Pegfilgrastim 
primary: 100ug/kg 
day 2 
29 1 Filgrastim primary: 
5ug/kg, from day 2 
up to 12d or until 
ANC=10x109/l 
31 11 
(median) 
#Studies added as a result of updated search. *Prophylaxis strategy: Primary prophylaxis is in all cycles. Secondary prophylaxis is in all cycles following FN†, or following FN or neutropenia††, or at 
physician’s discretion†††. DB=double-blind; OL=open-label, DF=dose-finding. NHL=non-Hodgkin’s lymphoma, HL= Hodgkin’s lymphoma, SCLC=small-cell lung cancer. FEC-100=5-fluorouracil 500mg/m2, 
epirubicin 100mg/m2, cyclophosphamide 500mg/m2. FEC-high-dose=5-fluorouracil 750mg/m2, epirubicin 35mg/m2, cyclophosphamide 400mg/m2. TAC= doxorubicin 50mg/m2, cyclophosphamide 500mg/m2, 
docetaxel 75mg/m2 CHOP=cyclophosphamide 750mg/m2, doxorubicin 50mg/m2, vincristine 1.4mg/m2, prednisolone 100mg days 1-5. R-CHOP=CHOP plus rituximab. ESHAP= etoposide 40mg/m2, 
methylprednisolone 500mg, cisplatin 25mg/m2/d, cytarabine 2000mg/m2. LNH-87=cyclophosphamide 1200mg/m2 day 1, vindesine 2mg/m2 days 1 & 5, bleomycin 10mg days 1 & 5, prednisolone 60mg/m2 
days 1-5, methotrexate 15mg, with either doxorubicin 75mg/m2 or mitoxantrone 12mg/m2 day 1. MAID=mesna, doxorubicin, ifosfamide, dacarbazine. CNOP=cyclophosphamide 750mg/m2, mitoxantrone 
10mg/m2, vincristine 1.4mg/m2, prednisolone 50mg/m2 days 1-5. VNCOP-B=vincristine 2mg, mitoxantrone 10mg/m2, cyclophosphamide 300mg/m2, etoposide 150mg/m2, prednisone 40mg, bleomycin 
10mg/m2. VAPEC-B=vincristine 1.4mg/m2, doxorubicin 35mg/m2 prednisolone 50mg/d (then tapered), etoposide 100mg/m2, cyclophosphamide 350mg/m2, bleomycin 10mg/m2. CDE=cyclophosphamide 
1g/m2, doxorubicin 45-50mg/m2, etoposide 100-120mg/m2. BEP/EP=etoposide 100mg/m2, cisplatin 20mg/m2, plus or minus bleomycin 30 U. BOP/VIP-B=bleomycin 30 U, vincristine 2mg, cisplatin 20-
50mg/m2/etoposide 100mg/m2, ifosfamide 1000mg/m2. 
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Table 2: Incidence of febrile neutropenia (FN) across all chemotherapy cycles in each study 
 
Study Total N 
(arm 1) 
FN rate (%) Total N 
(arm 2) 
FN rate (%) p-value Relative risk of FN 
(95% confidence 
interval) 
 Primary pegfilgrastim No primary G-CSF   
Vogel 2005‡‡ 463 6/463 (1.3%) 465 78/465  (17%) <0.001 0.08 (0.04-0.18) 
*Balducci 2007: solid tumour‡ 343  (4%) 343  (10%) 0.001 0.40 (0.22-0.73) 
*Balducci 2007: NHL‡ 73  (15%) 73  (37%) 0.004 0.41 (0.22-0.76) 
*Romieu 2007 (cycle 1 only)‡ 30 4/30 (13%) 29 5/29  (17%)  0.77 (0.23-2.62) 
*von Minckwitz 2008‡ 314 17/314 (5%) 253 55/253 (22%) <0.001 0.25 (0.15-0.43) 
 Primary filgrastim No primary G-CSF   
Doorduijn 2003‡‡‡ 197 72/197 (37%) 192 86/192 (45%) NR 0.82 (0.64-1.04) 
Osby 2003 (CHOP)‡‡ 101  (34%) 104  (50%) <0.001 0.68 (0.49-0.95) 
Osby 2003 (CNOP)‡‡ 125  (32%) 125  (50%) <0.001 0.64 (0.47-0.87) 
Zinzani 1997‡‡‡ 77 4/77 (5%) 72 15/72 (21%) 0.004 0.25 (0.09-0.73) 
Pettengell 1992‡ 41 9/41 (22%) 39 17/39 (44%) 0.04 0.50 (0.25-0.98) 
Timmer-Bonte 2005‡‡ 90 16/90 (18%) 85 27/85 (32%) 0.01 0.56 (0.33-0.96) 
Trillet-Lenoir 1993‡ 65 17/65 (26%) 64 34/64 (53%) 0.002 0.49 (0.31-0.78) 
Crawford 1991‡ 95  (40%) 104  (77%) <0.001 0.52 (0.4-0.68) 
Fossa 1998‡‡‡ 129 25/129 (19%) 130 38/130 (29%) NR 0.66 (0.42-1.03) 
 Primary lenograstim No primary G-CSF   
Chevallier 1995‡ 61 36/61 (59%) 59 42/59 (71%) NS 0.83 (0.64-1.08) 
Gisselbrecht 1997‡ 82 52/82 (63%) 80 62/80 (78%) NS 0.82 (0.67-1.0) 
Bui 1995 (cycle 1)‡ 22 5/22 (23%) 26 15/26 (58%) 0.02 0.39 (0.17-0.90) 
Gebbia 1994‡ 23 5/23 (22%) 28 18/28 (64%) <0.001 0.34 (0.15-0.77) 
Gebbia 1993‡ 43  (12%) 43  (33%) <0.05 0.36 (0.14-0.90) 
 Primary pegfilgrastim Primary filgrastim   
Green 2003‡‡ 77 10/77 (13%) 75 15/75 (20%) NS 0.65 (0.31-1.35) 
Holmes 2002: phase III‡‡ 149 14/149 (9%) 147 27/147 (18%) 0.029 0.51 (0.28-0.94) 
Holmes 2002: phase II‡‡ 46 5/46 (11%) 25 2/25 (8%)† NS 1.36 (0.28-6.49) 
Grigg 2003‡‡ 14 0/14 (0%) 13 1/13 (8%) NR N/A 
Vose 2003 (cycles 1 & 2)‡‡ 29 6/29 (21%) 31 6/31 (19%) NS 1.07 (0.39-2.95) 
FN=febrile neutropenia. ANC=absolute neutrophil count. *Studies added as a result of updated search. Febrile neutropenia definition: ‡fever and ANC <1x109/l; ‡‡fever and ANC <0.5x109/l; ‡‡‡FN not defined 
in terms of ANC. †Reported by Holmes et al. as 2/25=12%, which is incorrect; therefore the absolute numbers have been reported here (2/25), with the associated percentage (8%). 
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Table 3: Febrile neutropenia incidence: a) head-to-head meta-analysis; b) Bayesian mixed treatment comparison 
 
b) Bayesian mixed treatment comparison: 
 
Relative risk of FN (95% credible interval); 
probability T1 more effective than T2 in preventing FN (%) 
Treatment 1 (T1) Treatment 2 (T2) No of 
studies 
No of 
patients 
a) Head-to-head meta-analysis: 
 
Relative risk of FN (95% 
confidence interval); I2 statistic 
for heterogeneity (%) RCTs only: 
 
All studies: 
Pegfilgrastim No primary G-CSF RCTs: 
4* 
 
All studies:
5* 
RCTs: 
1819 
 
All studies: 
2386 
RCTs only: 
0.31 (0.12 – 0.76); I2=82.1% 
 
All studies: 
0.29 (0.15 – 0.55); I2=75.7% 
0.36 (0.22 – 0.61);  >99% 0.34 (0.23 – 0.54);  >99% 
Filgrastim No primary G-CSF 9 † 1835 0.61 (0.53 – 0.72); I2=28.7% 0.56 (0.44 – 0.68);  >99% 0.55 (0.43 – 0.67);  >99% 
Lenograstim No primary G-CSF 5 † 467 0.62 (0.44 – 0.88); I2=64.4% 0.49 (0.28 – 0.72);  >99% 0.49 (0.28 – 0.71);  >99% 
Pegfilgrastim 
 
Filgrastim 5 ‡ 606 0.64 (0.43 – 0.97); I2=0% 0.65 (0.39 – 1.11);    95% 0.62 (0.41 – 0.99);    98% 
Pegfilgrastim Lenograstim 0 0 No direct trials 
 
0.75 (0.38 – 1.60);    80% 0.71 (0.39 – 1.42);    86% 
Lenograstim 
 
Filgrastim 0 0 No direct trials 0.88 (0.49 – 1.40);    72% 0.88 (0.49 – 1.41);    71% 
*Pegfilgrastim vs no primary G-CSF: 5 studies in total; 4 RCTs (reported in 3 citations) and 1 non-randomised study. †As reported by Kuderer et al.[34] ‡As reported by Pinto et al.[35] 
 
 
